This inventor holds 1 USPTO granted patent. Top assignee: Stragen Pharma Sa. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Hervé Maisonneuve: Innovator in Leukemia Treatment
Introduction
Hervé Maisonneuve is a notable inventor based in La Roche sur Yon, France. He has made significant contributions to the field of medicine, particularly in the treatment of chronic myelogenous leukemia. His innovative approach has the potential to improve the lives of many patients suffering from this condition.
Latest Patents
Hervé Maisonneuve holds a patent for a method of treating chronic myelogenous leukemia that is resistant or intolerant to ST1571. This treatment involves the use of homoharringtonine, either alone or in combination with other agents. The invention specifically addresses the needs of patients suffering from chronic myelogenous leukemia, related myeloproliferative disorders, or Ph-positive acute lymphocytic leukemia. In a preferred embodiment, the method is applicable to human subjects.
Career Highlights
Hervé Maisonneuve is associated with Stragen Pharma SA, a company dedicated to advancing pharmaceutical research and development. His work at Stragen Pharma has allowed him to focus on innovative treatments that address critical health issues.
Collaborations
Hervé has collaborated with esteemed colleagues such as Jean-Pierre Robin and François-Xavier Mahon. These partnerships have fostered a collaborative environment that enhances the development of effective treatments.
Conclusion
Hervé Maisonneuve's contributions to leukemia treatment exemplify the impact of innovation in medicine. His patent and ongoing work at Stragen Pharma highlight the importance of research in improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile